Companies: 10,795·Total market cap: $144.5T
Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSCNASDAQHealthcare● Active
$0.25
$-0.00(-0.43%)
Market Cap$2347288
P/E Ratio
52W High$2.75
52W Low$0.23
Overview

Ensysce Biosciences, Inc. (ENSC) · Balance Sheet

Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.

FMP · ENSC · as of 2026-06-10

Financial statements

Total Assets · Total Liabilities · Equity
Breakdown2025-122024-122023-122022-122021-12
Assets
Cash & ST Investments$4.31M$3.50M$1.12M$3.15M$12.26M
Net Receivables$0.42M$0.12M$0.10M$0.28M$0.44M
Inventory$0.00M$0.00M$0.00M$0.00M($0.44M)
Total Current Assets$7.24M$5.34M$2.29M$5.30M$15.66M
PP&E Net$124129.00M$0.00M$0.00M$0.00M$24721.00M
Goodwill$0.00M$0.00M$0.00M$0.00M$0.00M
Intangible Assets$0.00M$0.00M$0.00M$0.00M$0.00M
Total Assets$7.45M$5.60M$2.71M$5.89M$16.42M
Liabilities
Short-Term Debt$306708.00M$0.30M$0.85M$4.27M$12.75M
Accounts Payable$3.27M$1.36M$1.94M$2.94M$0.30M
Total Current Liabilities$4.57M$2.21M$3.33M$9.46M$16.48M
Long-Term Debt$0.00M$0.00M$0.00M$0.14M$4.44M
Total Liabilities$4.57M$2.22M$3.36M$9.91M$24.58M
Stockholders Equity
Retained Earnings($139.72M)($129.54M)($121.56M)($110.93M)($85.85M)
Total Stockholders Equity$3.21M$3.71M($0.32M)($3.71M)($7.88M)
Total Liab & Equity(computed)$7.78M$5.93M$3.04M$6.20M$16.70M
Debt Summary
Total Debt$306708.00M$0.30M$0.85M$4.43M$17.21M
Net Debt$306703.69M($3.20M)($0.27M)$1.29M$4.95M

Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M

Explore more Ensysce Biosciences, Inc. data

About Ensysce Biosciences, Inc. (ENSC) Balance Sheet

Ensysce Biosciences, Inc. (ENSC) balance sheet shows total assets of $0.01B with cash of $0.00B. Total liabilities are $0.00B, total debt $306.71B, and stockholders equity $0.00B.

Frequently asked questions

ENSC · 4 questions

Ensysce Biosciences, Inc. has total debt of $306.71B with net debt of $306.70B.

ENSC total debtnet debtdebt to equity

· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10